Sabinsa has been granted U.S. patent US10166261 for a method of managing dementia and dementia-related sleep disorders presented as symptoms of major depressive disorder (MDD) in humans associated with Irritable Bowel Syndrome (IBS) by administering Bacillus coagulans MTCC 5856 (LactoSpore®) at a dose of 2 billion colony forming units per day. The patent also claims LactoSpore’s ability to reduce serum myeloperoxidase, an essential biochemical marker of MDD.
Sabinsa Issued New U.S. Patent for LactoSpore® Based upon Published Research Confirming Ability to Reverse Depression Symptoms in Patients Suffering from IBS
The patent application was supported by a recent clinical study, published in the peer-reviewed journal Food & Nutrition Research “Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, doubleblind, placebo controlled, multi-centre, pilot clinical study,” shelf-stable probiotic LactoSpore was reported to reduce depression symptoms in adults with IBS.
In a previously granted patent (US9579352), LactoSpore demonstrated that it alleviates the symptoms of IBS administered once a day, along with standard treatment of care. This latest patent, however, discloses the standalone effect of LactoSpore in improving the symptoms of IBS, along with the associated symptoms of MDD without co-administration of drugs, confirming that LactoSpore, by itself, is effective in managing psychological conditions associated with disorders in the gut, opening up a new avenue of research in the field of enteric-neurobiology and brain-gut-microbiome axis.
“It is gratifying that the US patent office recognized the strain specific action of Sabinsa’s MTCC 5856 in allowing the claims,” said Shaheen Majeed, President Worldwide, Sabinsa. “We anticipate being granted patents on the discovery in additional countries in the near future.”
The study may be accessed here: https://doi.org/10.29219/fnr.v62.1218